Liminatus Pharma, Inc. (LIMN)

Liminatus Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2023	FY 2023
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	-	-	-	0.86	0.2
Research & Development	-	-	-	1.85	3.8
Other Operating Expenses	0	0	0	-	-
Total Operating Expenses	0	0	0	2.71	4
Operating Income	-1.83	-0	-0	-2.71	-4
Interest Expense	-0.02	-	-	-0.22	-1.61
Other Non-Operating Income (Expense)	-1.1	-	-	-	-
Total Non-Operating Income (Expense)	-1.12	-	-	-0.22	-1.61
Pretax Income	-2.95	-0	-0	-2.93	-5.61
Net Income	-1.63	-0	-0	-2.93	-5.61
Net Income to Common	-1.63	-0	-0	-2.93	-5.61
Shares Outstanding (Basic)	19	7	3	7	7
Shares Outstanding (Diluted)	19	7	3	7	7
Shares Change (YoY)	528.84%	136.51%	-55.93%	-	-
EPS (Basic)	-0.41	-0.40	-0.15	-0.42	-0.81
EPS (Diluted)	-0.41	-0.40	-0.15	-0.42	-0.81
Free Cash Flow	-	-3.11	-2.09	-0.87	-0.17
Free Cash Flow Per Share	-	-0.43	-0.69	-	-
EBITDA	-1.83	-0	-0	-2.71	-4
EBIT	-1.83	-0	-0	-2.71	-4

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q